Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANEBNASDAQ:ELDNNASDAQ:KODNASDAQ:OGI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$1.00-4.8%$1.08$0.80▼$3.08$41.09M-1.1218,584 shs6,761 shsELDNEledon Pharmaceuticals$3.02-2.3%$3.08$2.30▼$5.54$185.04M0.08273,891 shs184,926 shsKODKodiak Sciences$3.45-3.4%$3.32$1.92▼$11.60$182.04M2.42345,573 shs590,286 shsOGIOrganigram$1.32-4.2%$1.13$0.85▼$2.08$176.95M1.35666,667 shs457,116 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals-5.09%-7.66%-13.14%-11.64%-50.00%ELDNEledon Pharmaceuticals-1.90%+2.32%-5.50%-25.54%+28.75%KODKodiak Sciences+2.00%+0.56%-14.18%-13.14%+21.02%OGIOrganigram+2.22%+0.73%+21.05%+20.00%-20.23%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANEBAnebulo Pharmaceuticals2.435 of 5 stars3.53.00.00.03.31.70.0ELDNEledon Pharmaceuticals2.7965 of 5 stars3.54.00.00.03.61.70.0KODKodiak Sciences4.1197 of 5 stars3.03.00.04.61.93.30.6OGIOrganigram1.1284 of 5 stars0.03.00.00.03.80.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANEBAnebulo Pharmaceuticals 3.00Buy$5.50450.00% UpsideELDNEledon Pharmaceuticals 3.00Buy$12.50313.91% UpsideKODKodiak Sciences 2.00Hold$9.00160.87% UpsideOGIOrganigram 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownLatest ANEB, OGI, ELDN, and KOD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025ANEBAnebulo PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $3.003/31/2025KODKodiak SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.00 ➝ $3.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.15 per shareN/AELDNEledon PharmaceuticalsN/AN/AN/AN/A$0.30 per shareN/AKODKodiak SciencesN/AN/AN/AN/A$5.07 per shareN/AOGIOrganigram$194.09M0.91N/AN/A$1.83 per share0.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANEBAnebulo Pharmaceuticals-$8.20M-$0.26N/A∞N/AN/A-119.54%-108.08%N/AELDNEledon Pharmaceuticals-$116.54M-$2.10N/AN/AN/AN/A-189.99%-28.17%8/18/2025 (Estimated)KODKodiak Sciences-$260.49M-$3.63N/AN/AN/AN/A-84.52%-45.40%8/13/2025 (Estimated)OGIOrganigram-$33.39M$0.10N/AN/AN/A-31.69%-8.59%-6.54%8/12/2025 (Estimated)Latest ANEB, OGI, ELDN, and KOD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ELDNEledon Pharmaceuticals-$0.28-$0.08+$0.20-$0.08N/AN/A5/14/2025Q1 2025KODKodiak Sciences-$0.89-$1.09-$0.20-$1.09N/AN/A5/13/2025Q3 2025ANEBAnebulo Pharmaceuticals-$0.05-$0.04+$0.01-$0.04N/AN/A3/27/2025Q4 2024KODKodiak Sciences-$0.90-$0.84+$0.06-$0.84N/AN/A3/20/2025Q4 2024ELDNEledon Pharmaceuticals-$0.32-$0.64-$0.32-$0.64N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/AOGIOrganigramN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANEBAnebulo PharmaceuticalsN/A17.5117.51ELDNEledon PharmaceuticalsN/A6.536.53KODKodiak SciencesN/A8.428.42OGIOrganigramN/A3.361.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANEBAnebulo Pharmaceuticals28.40%ELDNEledon Pharmaceuticals56.77%KODKodiak Sciences89.06%OGIOrganigram34.63%Insider OwnershipCompanyInsider OwnershipANEBAnebulo Pharmaceuticals80.60%ELDNEledon Pharmaceuticals12.30%KODKodiak Sciences45.30%OGIOrganigram0.09%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANEBAnebulo Pharmaceuticals441.09 million5.79 millionNot OptionableELDNEledon Pharmaceuticals1059.88 million52.75 millionOptionableKODKodiak Sciences9052.76 million28.79 millionOptionableOGIOrganigram860133.88 million126.10 millionOptionableANEB, OGI, ELDN, and KOD HeadlinesRecent News About These CompaniesTidal Investments LLC Sells 225,184 Shares of Organigram Holdings Inc. (NASDAQ:OGI)May 24, 2025 | marketbeat.comOrganigram (NASDAQ:OGI) Releases Earnings Results, Misses Expectations By $0.10 EPSMay 14, 2025 | marketbeat.comEarnings call transcript: OrganiGram’s Q2 2025 revenue surges 74%May 14, 2025 | uk.investing.comOrganiGram (OGI) Reports Q2 Loss, Beats Revenue Estimates (Revised)May 12, 2025 | zacks.comOrganiGram (OGI) Reports Q2 Loss, Misses Revenue EstimatesMay 12, 2025 | zacks.comInsights Ahead: OrganiGram Holdings's Quarterly EarningsMay 9, 2025 | benzinga.comOrganigram (OGI) to Release Earnings on MondayMay 7, 2025 | marketbeat.comOrganigram Global Wins "Exporter of the Year" at the 2025 New Brunswick Export AwardsMay 5, 2025 | finance.yahoo.comOrganigram Global Wins “Exporter of the Year” at the 2025 New Brunswick Export AwardsMay 5, 2025 | businesswire.comOrganigram to Report Second Quarter Fiscal 2025 Results on May 12, 2025May 2, 2025 | businesswire.comOrganigram Global’s Products Recognized at the CNB AwardsApril 24, 2025 | finance.yahoo.comOrganigram Global's Products Recognized at the CNB AwardsApril 24, 2025 | businesswire.comOrganigram Global Shares Recording of its OG Investor SessionApril 22, 2025 | businesswire.comOrganigram Global Announces Acquisition Of Collective Project Limited - Quick FactsApril 3, 2025 | nasdaq.comOrganigram Global Inc. (OGI.TO)April 2, 2025 | ca.finance.yahoo.comOrganigram Global to Host the OG Investor Session, its Inaugural Virtual Event for Investors, and Announcement of Name Change on TSX and NASDAQApril 2, 2025 | businesswire.comOrganigram acquires Collective Project for C$6.2MApril 2, 2025 | markets.businessinsider.comTop 5 cannabis stocks with operations in CanadaApril 1, 2025 | msn.comStocks in play: Organigram Global Inc.April 1, 2025 | ca.finance.yahoo.comOrganigram Enters U.S. Through Acquisition of Collective Project BeveragesApril 1, 2025 | businesswire.comOrganigram Rebrands to Reflect Global Expansion AmbitionsMarch 26, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsQuantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?By Jeffrey Neal Johnson | May 22, 2025View Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?3 Tech Leaders Announce Buybacks Totaling $85 BillionBy Leo Miller | May 5, 2025View 3 Tech Leaders Announce Buybacks Totaling $85 BillionThe Top 3 Stock Picks at the World’s Greatest Hedge FundBy Leo Miller | May 2, 2025View The Top 3 Stock Picks at the World’s Greatest Hedge Fund3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any MarketBy Chris Markoch | May 22, 2025View 3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any MarketANEB, OGI, ELDN, and KOD Company DescriptionsAnebulo Pharmaceuticals NASDAQ:ANEB$1.00 -0.05 (-4.76%) Closing price 03:48 PM EasternExtended Trading$1.00 0.00 (0.00%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Eledon Pharmaceuticals NASDAQ:ELDN$3.02 -0.07 (-2.27%) Closing price 04:00 PM EasternExtended Trading$3.00 -0.02 (-0.66%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Kodiak Sciences NASDAQ:KOD$3.45 -0.12 (-3.36%) Closing price 04:00 PM EasternExtended Trading$3.40 -0.05 (-1.45%) As of 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Organigram NASDAQ:OGI$1.32 -0.06 (-4.22%) Closing price 04:00 PM EasternExtended Trading$1.34 +0.02 (+1.38%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
